Agilon Health Inc ((AGL)) has held its Q2 earnings call. Read on for the main highlights of the call.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Agilon Health’s latest earnings call struck a cautiously optimistic tone as management showcased a sharp financial turnaround alongside improved clinical execution and data capabilities. While acknowledging persistent cost pressures, shrinking Medicare Advantage membership and uncertainties beyond 2026, executives argued that stronger margins, better risk adjustment and disciplined contracting lay the groundwork for more durable profitability.

Revenue Growth and Upgraded Top-Line Outlook

Revenue in the second quarter rose about 7.1% year over year to roughly $1.5 billion, up from $1.4 billion in the prior period and ahead of expectations. On the back of this momentum and improved visibility, Agilon raised its full-year 2026 revenue guidance midpoint to approximately $5.8 billion, signaling confidence despite volume headwinds.

Medical Margin Swings Sharply into Positive Territory

Medical margin flipped from a loss of about $53 million in last year’s second quarter to a positive $197 million this year, an absolute improvement near $250 million. The latest result exceeded midpoint guidance by roughly $74 million, underscoring better-than-expected performance in managing medical costs and capturing risk-adjusted revenue.

Adjusted EBITDA Returns to the Black

Adjusted EBITDA rebounded to approximately $70 million in the quarter, versus a loss of about $83 million a year prior, marking roughly $153 million of improvement. This figure beat the company’s Q2 midpoint guidance by around $50 million, prompting management to lift full-year adjusted EBITDA guidance to about $85 million.

Risk Adjustment and Diagnosis Programs Drive Uplift

Enhanced data tools and the Burden of Illness program delivered a larger risk adjustment uplift than previously forecast, now pegged near 3% year over year net of V28 changes. Year-to-date, management cited roughly $38 million of medical margin benefit and about $20 million of adjusted EBITDA contributions tied to these efforts, reinforcing the value of more accurate coding and documentation.

Clinical Pathways Boost CHF and ACO REACH Results

The company’s heart failure clinical pathway, now deployed in about 90% of markets, has dramatically reduced inpatient “first diagnosis” rates within the network from roughly 25% to under 5%. In ACO REACH, Agilon reported $229 million in gross savings for the 2024 performance year and an average quality score of 96% across eight accountable care organizations, highlighting both cost discipline and quality outcomes.

Data Pipeline Expansion Enhances Visibility

Agilon’s enhanced data pipeline now captures information from more than 80% of payer partners, improving midyear visibility into metrics such as MAO-4 and MMR feeds. This broader data coverage allows earlier identification of high-risk patients and tighter tracking of revenue and cost trends, supporting more reliable forecasting and operational decisions.

Cost Trend Moderates but Remains a Watch Point

Management reported improved cost development, revising full-year 2025 medical cost trend down to 5.8% from 6.2% and guiding Q1 2026 trends into the low-6% range. However, Q2 costs were recorded in the low-7% range due to limited paid claims visibility and conservative reserving, and guidance assumes roughly 7% cost trend for the remaining quarters, signaling continued caution.

Liquidity Profile Supports Ongoing Investments

The company ended the quarter with $257 million of cash and marketable securities and an additional $83 million of off-balance-sheet ACO cash, for total available liquidity of around $340 million. Agilon expects to exit 2026 with at least $125 million in cash, implying sufficient capacity to fund its data, AI and clinical pathway initiatives while weathering cost and membership volatility.

Medicare Advantage Membership Decline Reflects Discipline

Medicare Advantage membership fell to about 437,000 members in the second quarter, down roughly 61,000 from 498,000 a year earlier, equating to a 12.3% decline. Management framed this drop as a deliberate outcome of profitability-focused contracting for 2026, emphasizing that shedding less attractive arrangements is key to sustaining margins even at the expense of near-term growth.

ACO REACH Membership Sees Modest Pullback

ACO REACH membership slipped to roughly 112,000 in the quarter from 116,000 a year ago, a decrease of about 3.4%. While modest, this decline illustrates that Agilon is not aggressively chasing volume in its government programs, instead balancing membership levels against financial performance and operational capacity.

Cost Trend Risk and Conservative Reserving Strategy

Despite favorable early cost trends, management stressed that limited claims run-out necessitates a conservative stance, including recording Q2 trends in the low-7% range. The company’s full-year assumptions embed approximately 7% cost trend for the remaining quarters, signaling that inflationary pressures and utilization risk are still very much in focus.

Part D Exposure Adds Seasonal Complexity

Although less than 15% of Agilon’s book is exposed to Part D, this segment remains a source of complexity in both seasonality and revenue recognition. Prior-year Part D accruals affected comparability and contributed to cautious reserving, leading management to emphasize ongoing vigilance around this line of business despite its limited share of overall membership.

Uncertain 2027 Contracting and Membership Trajectory

Details around 2027 contracting and bids are still evolving, leaving the path for membership and pricing beyond 2026 somewhat unclear. Management noted that negotiations with payers will conclude later in the year, acknowledging that the eventual terms will heavily influence future growth, margins and the mix between Medicare Advantage and ACO programs.

Measured Approach to New Market Expansion

The company is keeping a measured pace on entering new markets, with implementation timelines of roughly 12 to 18 months and a focus on deepening performance in existing geographies. While this limits near-term upside from rapid geographic expansion, management believes the strategy enhances execution quality and supports more durable, market-level profitability.

Guidance Highlights and Outlook

Agilon raised its full-year 2026 outlook to about $5.8 billion in revenue, roughly $485 million in medical margin and approximately $85 million in adjusted EBITDA, including $25–30 million from ACO REACH. For the third quarter, the company is guiding to around $1.46 billion in revenue, medical margin near $110 million and roughly break-even adjusted EBITDA, implying a more tempered near-term run rate as cost trends and membership pressures are absorbed.

Agilon’s earnings call painted the picture of a company transitioning from a volume-driven growth model to a more disciplined, profitability-centered platform underpinned by better data and clinical programs. Investors will need to weigh near-term headwinds in membership and cost volatility against the clear gains in margin, risk adjustment and visibility that management believes can sustain momentum into 2026 and beyond.